Providing funding, expertise and resources to translate breakthroughs in neurodegeneration research into new dementia treatments
The Dementia Consortium aims to expedite the development of new drugs for dementia by supporting research into novel targets for neurodegeneration. It brings together the voluntary, academic and private sectors in order to tackle the growing dementia problem. The Consortium seeks to end the ten-year wait for a new dementia treatment by closing the gap between fundamental academic research and the pharmaceutical industry’s drug discovery programmes. It provides funding, expertise and resources to support new drug targets emerging from academic research that hold the promise of patient benefit.
The consortium members are making four key commitments:
The Consortium has put together a fund of £4.5 million to support the best academic research from both the UK and the rest of the world. Applicants should submit details of novel drug targets which have been discovered through their work in neurodegeneration for review by a specialist dementia and drug discovery panel.
The Consortium will invest in research projects, typically 2-3 years in duration, to support target validation and explore the tractability of the target for drug discovery in collaboration with the Consortium members.
The Consortium will fund drug discovery programmes on selected targets in parallel with the basic research. Work will take place within academia, in collaboration with LifeArc’s dedicated small molecule and antibody drug discovery laboratories.
Applicants and all members of the Consortium will help progress successful projects from laboratories towards the clinic, seeing new therapies delivered to patients and sharing in the financial returns.
The Consortium unites the charity Alzheimer’s Research UK with technology transfer experts LifeArc and five pharmaceutical companies, AbbVie, Astex, Eisai, MSD and Lilly. Further information about the Consortium members is available here.
Launch event slides and videos
For more information about the Consortium and the application process please download the slides from the launch event. You can also watch videos of the launch presentations and Q&A session:
- ARUK – Introduction to ARUK’s strategy and the Dementia Consortium
- Lilly – Introduction to Lilly and their role in the Consortium
- LifeArc (previous name MRC Technology) – Introduction to MRC Technology and their role in the Consortium
- ARUK – Goals and model for the Consortium and about target validation
- LifeArc (previous name MRC Technology) - Resources available within the Consortium for target validation and expected project outcomes
- LifeArc (previous name MRC Technology) - About the application process and what we’re looking for
- Question and answer session